Hôpital Edouard Herriot

Running trials

• Not yet recruiting

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Hospices Civils de Lyon· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies

  NCT07837986· Hospices Civils de Lyon· Source

• Not yet recruiting

  Assessment of the Preventive Effect of Defusing on Traumatic Kindling

  NCT07850193· Hospices Civils de Lyon· Source

• Recruiting

  Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

  2026-526775-27-00· Phase 2· Laboratoires Kol· Source

• Not yet recruiting

  Real-world Evaluation of Different Endoscopic Biliary Drainage Techniques in Patients With Jaundice of Biliopancreatic Malignant Origin

  NCT07817602· Centre Hospitalier Universitaire de Nīmes· Source

• Recruiting

  A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

  NCT07656415· Phase 3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  2025-523670-17-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor

  NCT07471425· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial

  NCT07506473· University Hospital, Grenoble· Source

• Recruiting

  Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo

  NCT07152626· Phase 2· Centre Hospitalier Universitaire de Nice· Source

• Recruiting

  Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection

  NCT07343869· Société Française d'Endoscopie Digestive· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  MAIT Cells in Hidradenitis Suppurativa

  NCT07388446· Hospices Civils de Lyon· Source

• Not yet recruiting

  Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

  NCT07379957· University Hospital, Bordeaux· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies

  NCT02670447· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology

  NCT07260617· Hospices Civils de Lyon· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function

  NCT07268508· Hospices Civils de Lyon· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )

  NCT06731244· University Hospital, Brest· Source

• Recruiting

  Evaluation of Performances, Clinical Benefits and Safety of the 'Audiocap' Connected Hearing Rehabilitation Device for Improving Audibility in Hearing-impaired People in the Context of CE Marking - AUDIOCAP-2

  NCT07252492· Archean Technologies· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study

  2024-514647-29-01· Phase 2· Centre Hospitalier Universitaire De Nice· Source

• Recruiting

  Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?

  NCT06742333· Phase 2· Centre Hospitalier Universitaire de Nice· Source

• Not yet recruiting

  Study of Fecal Microbiota Transplantation (FMT) in Severe IBS Patients

  NCT06433180· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

  NCT06350630· Phase 2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Active, not recruiting

  Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

  NCT06956235· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes

  NCT07006272· University Hospital, Grenoble· Source

• Active, not recruiting

  A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

  NCT06924970· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.

  NCT06776965· Hospices Civils de Lyon· Source

• Recruiting

  Capsaicin in Digital Osteoarthritis Versus Control

  NCT06444919· Phase 4· University Hospital, Clermont-Ferrand· Source

• Recruiting

  Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  NCT06855498· Phase 3· Incyte Corporation· Source

• Recruiting

  Single-center Exploratory Study of the Intestinal Microbiota in Patients Treated for Irritable Bowel Syndrome With Predominant Constipation and Methane Production

  NCT06801184· Hospices Civils de Lyon· Source

• Not yet recruiting

  Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation

  NCT06619093· Hospices Civils de Lyon· Source

• Not yet recruiting

  Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

  NCT06595680· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)

  NCT06614738· Hospices Civils de Lyon· Source

• Not yet recruiting

  Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

  NCT06356740· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver

  NCT04659382· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

  NCT05373264· Phase 3· University Medical Center Groningen· Source

• Active, not recruiting

  A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.

  2023-507684-19-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Active, not recruiting

  A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

  NCT06118411· Phase 3· AbbVie· Source

• Recruiting

  Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

  NCT05918302· Phase 3· Grupo Espanol de Tumores Neuroendocrinos· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

  NCT05889182· Phase 3· AbbVie· Source

Showing 50 of 82.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Neuroendocrine tumours6 recruiting
• Pancreatic cancer6 recruiting
• Colorectal cancer5 recruiting
• Deep vein thrombosis and pulmonary embolism4 recruiting
• Macular degeneration4 recruiting
• Chronic kidney disease3 recruiting
• Liver and biliary tract cancer3 recruiting
• Lupus (SLE)3 recruiting
• Barrett's oesophagus2 recruiting
• Bladder cancer2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Hepatitis B2 recruiting
• Hidradenitis suppurativa2 recruiting
• Irritable bowel syndrome2 recruiting
• Lung cancer2 recruiting
• Osteoarthritis2 recruiting
• Psoriasis2 recruiting
• Rheumatoid arthritis2 recruiting
• Sickle cell disease2 recruiting
• Vitiligo2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Polycystic kidney disease1 recruiting
• Prostate cancer1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thymoma and thymic carcinoma1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

  NCT05979441· Phase 3· argenx· Source

• Completed

  Intubation of Obese Patients in the Operating Room With or Without Face Mask Ventilation

  NCT05930678· Nantes University Hospital· Source

• Completed

  T1 Mapping in Fabry Disease

  NCT05923788· Hospices Civils de Lyon· Source

• Completed

  A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

  NCT05901649· Janssen-Cilag Ltd.· Source

• Terminated

  Hidradenitis Suppurativa Study of Izokibep

  NCT05905783· Phase 3· ACELYRIN Inc.· Source

• Active, not recruiting

  A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

  NCT05785611· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT05620836· Phase 3· Incyte Corporation· Source

• Completed

  Different Doses of Naronapride vs. Placebo in Gastroparesis

  NCT05621811· Phase 2· Dr. Falk Pharma GmbH· Source

• Completed

  SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

  NCT05628233· Phase 2· Sensorion· Source

• Completed

  Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter

  2024-511896-13-00· Phase 4· Assistance Publique Hopitaux De Paris· Source

• Terminated

  A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

  NCT05462990· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Completed

  Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis

  NCT05248386· Phase 3· Grünenthal GmbH· Source

• Completed

  Evaluation of the Presence of SENS-401 in the Perilymph

  NCT05258773· Phase 2· Sensorion· Source

• Completed

  A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

  NCT05254002· Phase 2· Bayer· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Amgen· Source

• Completed

  Lifestyle Intervention After Colonoscopy (LIFE-SCREEN Pilot)

  NCT05273931· Centre Leon Berard· Source

• Completed

  Transcutaneous Oxygen Pressure (TcPO2) Determination.

  NCT05192707· Hospices Civils de Lyon· Source

• Completed

  Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.

  NCT04853914· EDAP TMS S.A.· Source

• Recruiting

  Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

  NCT04605146· Hospices Civils de Lyon· Source

• Completed

  Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

  NCT04739202· Phase 2· Hospices Civils de Lyon· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Daiichi Sankyo· Source

• Completed

  Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953· Phase 3· The George Institute· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Links Between Cognitive Functions and Clinical, Biological and Neuroradiological Outcomes in Adults With Sickle Cell Disease.

  NCT04244240· Hospices Civils de Lyon· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  DOAC in Unusual Site Venous Thrombosis

  NCT03778502· University of Malta· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Theravia· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source

• Active, not recruiting

  A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

  NCT03816163· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Source

• Completed

  Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT03827798· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

  NCT03818035· Phase 3· Janssen-Cilag International NV· Source

• Completed

  Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

  NCT03591731· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort)

  NCT03695796· University Hospital, Angers· Source

• Completed

  Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric Bypass

  NCT03610256· Hospices Civils de Lyon· Source

• Completed

  Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  NCT03568188· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

  NCT03364530· Phase 2· University Hospital, Montpellier· Source

• Completed

  Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

  NCT02797314· Hospices Civils de Lyon· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source

• Completed

  French Assessment of the Relay Plus and Relay NBS Plus Thoracic Stent-Graft

  NCT05030740· Vascutek Ltd.· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Neuroendocrine tumours12 works · 10 trials
• Hidradenitis suppurativa7 works · 8 trials
• Dermatomyositis and polymyositis (myositis)4 works · 4 trials
• Barrett's oesophagus4 works · 2 trials